← Eichor
Condition: Metastatic Hormone Receptor Positive Breast Carcinoma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Metastatic Hormone Receptor Positive Breast Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study of XB010 in Subjects With Solid Tumors
Phase 1 · 20 location(s) · Exelixis · NCT06545331A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT04683679DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer Patients
Phase N/A · 1 location(s) · Mayo Clinic · NCT06388122Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Br
Phase 1/Phase 2 · 3 location(s) · Washington University School of Medicine · NCT06374459AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
Phase 1 · 3 location(s) · Avacta Life Sciences Ltd · NCT07454642Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors,
Phase N/A · 1 location(s) · Hunan Cancer Hospital · NCT07073755Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/
Phase 1/Phase 2 · 14 location(s) · Ellipses Pharma · NCT05573126Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM
Phase 2 · 1 location(s) · Brown University · NCT06974604PRE-I-SPY Phase I/Ib Oncology Platform Program
Phase 1 · 7 location(s) · QuantumLeap Healthcare Collaborative · NCT05868226Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or
Phase 3 · 88 location(s) · Daiichi Sankyo · NCT05950945Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer
Phase 1/Phase 2 · 1 location(s) · Nagoya City University · NCT07164976Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial)
Phase 3 · 3 location(s) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT05904964BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Phase 1 · 63 location(s) · BeOne Medicines · NCT06120283Sac-TMT Plus KL-A167 in PD-L1+, HR+/HER2- Metastatic Breast Cancer After CDK4/6 Inhibitors
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT07258108Mobile Health for Adherence in Breast Cancer Patients
NA · 506 location(s) · ECOG-ACRIN Cancer Research Group · NCT06112613Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Phase 1/Phase 2 · 66 location(s) · Genmab · NCT05579366Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases
Phase 1/Phase 2 · 2 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT04923542Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer
Phase 2 · 1 location(s) · Mayo Clinic · NCT06525766A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
Phase 1 · 12 location(s) · Aktis Oncology, Inc. · NCT07020117Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative B
Phase 2 · 3 location(s) · Roswell Park Cancer Institute · NCT04348747FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer
Phase 1 · 8 location(s) · Regor Pharmaceuticals Inc. · NCT05304962A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Phase 3 · 195 location(s) · Merck Sharp & Dohme LLC · NCT07060807Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
Phase 2 · 3 location(s) · Reshma L. Mahtani, D.O. · NCT06263543Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Can
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT07610720A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated,
Phase N/A · 28 location(s) · Hoffmann-La Roche · NCT07347600Artificial Intelligence and Machine Learning to Guide CDK4/6 Inhibitor Rechallenge in Breast Cancer.
Phase 2 · 1 location(s) · University of California, San Diego · NCT07227233A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT06678269A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Meta
Phase 2 · 53 location(s) · Puma Biotechnology, Inc. · NCT06369285Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast
Phase 2 · 2 location(s) · University of Washington · NCT06179303Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
Phase 3 · 284 location(s) · AstraZeneca · NCT04862663
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.